More ideas from Jason
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020.  Enquiry @ http://www.researchbeam.com/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-to-2020-novel-technologies-show-considerable-promise-in-relapsedrefractory-setting-market/enquire-about-report

Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting

Treatment and prognosis in AML is strongly influenced by a patient’s age, and their cytogenetic profile. In the majority of cases these two prognostic influences are linked, with a higher frequency of unfavorable cytogenetic abnormalities observed in the elderly.  Enquiry @ http://www.researchbeam.com/acute-myeloid-leukemia-therapeutics-to-2020-novel-therapies-to-offer-clinical-benefit-in-small-patient-cohorts-market/enquire-about-report

Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts

This report provides comprehensive information on the current therapeutic developmental pipeline of Agios Pharmaceuticals Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type.  Enquiry @  http://www.researchbeam.com/agios-pharmaceuticals-inc-product-pipeline-review-2015-market/enquire-about-report

Find out how you can join the experts in a discussion about the most profitable investments in the biotechnology .

Research Beam added a report “Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth: Size, Share, Trends, Segmentation, Growth, Technology, Opportunity, Analysis and forecast"  Enquiry @ http://www.researchbeam.com/melanoma-therapeutics-to-2020-rising-prevalence-and-evolving-treatment-algorithms-to-drive-growth-market/enquire-about-report

Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth

GBI Research, the leading business intelligence provider, has released its latest research: Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics, which provides in-depth analysis of the Colorectal Cancer Enquiry @ http://www.researchbeam.com/colorectal-cancer-therapeutics-in-major-developed-to-2020-increased-uptake-of-high-priced-drugs-to-offset-the-impact-of-generics-market/enquire-about-report

Colorectal Cancer Therapeutics in Major Developed Markets to Uptake of High Priced Drugs to Offset the Impact of Generics

The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market.  Enquiry @ http://www.researchbeam.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

This report provides comprehensive information on the current therapeutic developmental pipeline of Patrys Limited s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  Enquiry @  http://www.researchbeam.com/patrys-limited-product-pipeline-review-2015-market/enquire-about-report

This report provides comprehensive information on the current therapeutic developmental pipeline of Patrys Limited s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Enquiry @ http://www.researchbeam.com/patrys-limited-product-pipeline-review-2015-market/enquire-about-report

GBI Research, a leading business intelligence provider, has released its latest research report, Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations.  Enquiry @ http://www.researchbeam.com/asthma-therapeutics-in-major-developed-to-2020-personalized-treatment-for-severe-asthma-to-drive-growth-despite-patent-expirations-market/enquire-about-report

Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations

The Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD) pipeline consists of 84 molecules across all stages of development. GBI Researchs analysis revealed a high degree of innovation and diversity in this indication, with 70% of the pipeline being first-in-class products.  Enquiry @ http://www.researchbeam.com/frontier-pharma-duchenne-muscular-dystrophy-and-becker-muscular-dystrophy-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report

Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation

GBI Researchs report, MRI Systems Market to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies discusses the market, competitive landscape, and trends for three MRI systems market segments: High-field, Mid-field, and Low-field MRI systems.  Enquiry @ http://www.researchbeam.com/mri-systems-to-2020-focus-on-patient-comfort-and-operational-efficiency-with-growth-driven-by-developing-economies-market/enquire-about-report

MRI Systems Market to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies

The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. Enquiry @ http://www.researchbeam.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market/enquire-about-report

Psoriasis Therapeutics in Asia-Pacific Markets to Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000.  Enquiry @ http://www.researchbeam.com/multiple-myeloma-therapeutics-in-major-developed-to-2021-growth-driven-by-rising-prevalence-continued-success-of-revlimid-and-emerging-supplementary-treatments-market/enquire-about-report

POTENTIAL THERAPY - Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity.  Enquiry @ http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-major-developed-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021